NLM Digital Collections

Search

Start Over Subjects Cost-Benefit Analysis ✖Remove constraint Subjects: Cost-Benefit Analysis Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later Publication Year 2000 to 2024 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2024">2024</span>

32. Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Cost-Benefit Analysis
Evidence-Based Medicine
Insurance Coverage -- economics
Technology Assessment, Biomedical
Formularies as Topic
Medicaid -- economics
Medicare -- economics
Private Sector
State Government
Humans
United Kingdom
United States
United States. Agency for Healthcare Research and Quality.
Blue Cross Association.
Blue Shield Association.
Centers for Medicare & Medicaid Services (U.S.)
National Institute for Health and Clinical Excellence (Great Britain)

33. Show me the money: economic evaluations of opioid use disorder interventions

Author(s):
Murphy, Sean M., author
Polsky, Daniel, author
Meisel, Zachary, author
Mitchell, Julia, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016
Subject(s):
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Buprenorphine -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Reward
Humans
United States

35. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
Subject(s):
Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States

36. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):
Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States

37. Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
Subject(s):
Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States

38. Elagolix for treating endometriosis: final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

39. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States

40. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States

Refine by: